Phathom Pharmaceuticals, Inc. – FDA 483, Jul 31, 2026

An FDA inspection of Phathom Pharmaceuticals, Inc., a corporate headquarter in Buffalo Grove, IL, identified one observation related to postmarketing safety reporting. The firm failed to include copies of published scientific articles with expedited 15-day Alert reports submitted to the FDA. This indicates a deficiency in documentation practices for adverse event reporting.